for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Anavex Life Sciences Corp

AVXL.OQ

Latest Trade

5.82USD

Change

-0.10(-1.69%)

Volume

189,465

Today's Range

5.75

 - 

6.24

52 Week Range

2.21

 - 

7.69

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
5.92
Open
5.97
Volume
189,465
3M AVG Volume
28.30
Today's High
6.24
Today's Low
5.75
52 Week High
7.69
52 Week Low
2.21
Shares Out (MIL)
66.96
Market Cap (MIL)
389.72
Forward P/E
-12.52
Dividend (Yield %)
--

Next Event

Anavex Life Sciences Corp Annual Shareholders Meeting

Latest Developments

More

Anavex Life Sciences Reports Fiscal 2020 Year End Financial Results And Clinical Program Updates

Anavex Life Sciences Announces Anavex 2-73 (Blarcamesine) Meets Primary And Secondary Endpoints

Anavex Life Sciences Announces Positive Results On Phase 2 Clinical Trial In Parkinson’S Disease Dementia

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Anavex Life Sciences Corp

Anavex Life Sciences Corp. is a clinical-stage biopharmaceutical company. The Company is engaged in the development of differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases, including drug candidates to treat Alzheimer's disease (AD), other central nervous system (CNS) diseases, pain and various types of cancer. Its research and development pipeline includes a clinical drug candidate and various compounds in different stages of pre-clinical study. Its product pipeline also includes ANAVEX 2-73, ANAVEX 3-71, ANAVEX 1-41, ANAVEX 1037 and ANAVEX 1066. The Company's SIGMACEPTOR Discovery Platform produces small molecule drug candidates with modes of action, based on its understanding of sigma receptors. ANAVEX 1-41 is a sigma-1 agonist. ANAVEX 1066 is a mixed sigma-1/sigma-2 ligand. As of September 30, 2016, the Company had not generated any revenues from its operations.

Industry

Business Services

Contact Info

51 W 52nd St Fl 7th

NEW YORK, NY

10019-6163

United States

+1.800.6893939

https://www.anavex.com

Executive Leadership

Christopher U. Missling

President, Chief Executive Officer, Secretary, Director

Sandra Boenisch

Principal Financial Officer, Treasurer

Peter Donhauser

Independent Director

Elliot J. Favus

Independent Director

Athanasios Skarpelos

Independent Director

Key Stats

1.75 mean rating - 4 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2019

0.0K

2020

0.0K

2021(E)

0.0K
EPS (USD)

2018

-0.390

2019

-0.540

2020

-0.450

2021(E)

-0.465
Price To Earnings (TTM)
--
Price To Sales (TTM)
--
Price To Book (MRQ)
13.26
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
0.00
LT Debt To Equity (MRQ)
0.00
Return on Investment (TTM)
-110.59
Return on Equity (TTM)
-87.79

Latest News

Latest News

BRIEF-Anavex Life Sciences Announces First Participant Enrolled In Phase 1 Study Of Anavex 3-71

* ANAVEX LIFE SCIENCES ANNOUNCES FIRST PARTICIPANT ENROLLED IN PHASE 1 STUDY OF ANAVEX®3-71 (AF710B) Source text for Eikon: Further company coverage:

BRIEF-Anavex Life Says Co & Lincoln Park Capital Fund Entered Into First Amendment To Purchase Agreement

* ANAVEX LIFE SCIENCES - ON JULY 1, CO & LINCOLN PARK CAPITAL FUND, LLC ENTERED INTO FIRST AMENDMENT TO PURCHASE AGREEMENT

BRIEF-Anavex Life Sciences Announces Exceeding Of Enrollment Target For Anavex2-73 U.S. Phase 2 Rett Syndrome Clinical Trial

* ANAVEX LIFE SCIENCES ANNOUNCES EXCEEDING OF ENROLLMENT TARGET FOR THE ANAVEX®2-73 (BLARCAMESINE) U.S. PHASE 2 RETT SYNDROME CLINICAL TRIAL

BRIEF-Anavex Life Sciences Announces Initiation Of First-In-Human Phase 1 Study Of Anavex®3-71

* ANAVEX LIFE SCIENCES ANNOUNCES INITIATION OF FIRST-IN-HUMAN PHASE 1 STUDY OF ANAVEX®3-71 (AF710B) Source text for Eikon: Further company coverage: (Reuters.Briefs@thomsonreuters.com)

BRIEF-Anavex Life Sciences Q2 Loss Per Share $0.12

* ANAVEX LIFE SCIENCES REPORTS FISCAL 2020 SECOND QUARTER FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATES

BRIEF-Anavex Life Sciences Corp Files Prospectus Supplement Related To Issuance, Sale Of Up To $30.3 Million In Common Shares To Lincoln Park Capital Fund, Llc

* ANAVEX LIFE SCIENCES CORP FILES PROSPECTUS SUPPLEMENT RELATES TO ISSUANCE, SALE OF UP TO $30.3 MILLION IN COMMON SHARES TO LINCOLN PARK CAPITAL FUND, LLC Source text for Eikon: [ID: https://bit.ly/3bV33mP] Further company coverage:

BRIEF-Anavex Life Sciences Corp - May Offer And Sell Shares Of Common Stock Having Offering Price Of Up To $50 Million From Time To Time

* ANAVEX LIFE SCIENCES CORP - MAY OFFER AND SELL SHARES OF COMMON STOCK HAVING OFFERING PRICE OF UP TO $50 MILLION FROM TIME TO TIME - SEC FILING Source text for Eikon: [ID: https://bit.ly/2WkFZY2] Further company coverage:

BRIEF-Anavex Life Sciences Announces Publication Of Foundational Data For Anavex®2-73 In Multiple Sclerosis

* ANAVEX LIFE SCIENCES ANNOUNCES PUBLICATION OF FOUNDATIONAL DATA FOR ANAVEX®2-73 (BLARCAMESINE) IN MULTIPLE SCLEROSIS (MS)

BRIEF-BBI Life Sciences Refers To Announcement By Co & LJ Future For Proposed Privatisation

* BBI LIFE SCIENCES CORP REFERS TO ANNOUNCEMENT BY CO & LJ FUTURE, AS OFFEROR, FOR PROPOSED PRIVATISATION OF CO

BRIEF-Anavex Life Sciences Reports Q2 Loss Per Share Of $0.11

* ANAVEX LIFE SCIENCES REPORTS FISCAL SECOND QUARTER 2018 FINANCIAL RESULTS

BRIEF-Anavex Life Sciences To Initiate Phase 2 Study Of Anavex®2-73 In Parkinson’S Disease Dementia

* ANAVEX LIFE SCIENCES TO INITIATE PHASE 2 STUDY OF ANAVEX®2-73 IN PARKINSON’S DISEASE DEMENTIA AND PROVIDES CLINICAL STUDY UPDATE FOR ANAVEX®2-73 IN RETT SYNDROME

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up